If there was one disease where we could use a break it would be Lupus. Well okay, scleroderma too, you're right. And I think just about everybody had high hopes for rituximab, B-cell depletion in SLE seemed like a gimmee. The results are in, however, and they couldn't look much worse. In a tear-stained release by Genentech we find that rituximab did no good during a 52 week trial of non-nephritic lupus patients. It didn't reach either of it's primary endpoints nor any of it's six secondary endpoints. The trial appears pointless. To be optimistic, however, there is still an ongoing trial in lupus nephritis. Don't hold your breath. Of course, there's always scleroderma.